Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Common arthritis drug also lowers blood pressure

Scientists have known for a while that methotrexate helps with inflammation, but it may also help...

AI enables precise gene editing

A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...

Shingles vaccine may reduce risk of heart attack and stroke 

Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...

Content from other channels on our network

FieldComm Group announces unified device integration roadmap

WA announces legislation to drive industry investment

Livium and UoM partner on microwave technology for REE extraction

Australia moves towards Horizon Europe membership

Mitsubishi Electric to acquire Nozomi Networks

New food safety regulator for Victoria

Discovery improves flavour of Chinese spirits

Hyperspectral imaging for food grading

Walkers Chocolates introduces recyclable paper wrapper

Australians back egg industry amid biosecurity concerns

Tas doctors "strongly oppose" any taxpayer-funded home birth scheme

Perich Centre for Robotics & Health Technology opens in Liverpool

Australia will soon have its own 'centre for disease control'. Let's not repeat the chaos of the US

Report: Sepsis more prevalent, deadly and costly than previously understood

Patient-centric digital pathway seeks to transform short-stay surgery